BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 34677784)

  • 1. Endogenous testosterone density as ratio of endogenous testosterone levels on prostate volume predicts tumor upgrading in low-risk prostate cancer.
    Porcaro AB; Gallina S; Bianchi A; Cerrato C; Tafuri A; Rizzetto R; Amigoni N; Orlando R; Serafin E; Gozzo A; Migliorini F; Antoniolli SZ; Lacola V; De Marco V; Brunelli M; Cerruto MA; Siracusano S; Antonelli A
    Int Urol Nephrol; 2021 Dec; 53(12):2505-2515. PubMed ID: 34677784
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Endogenous testosterone density predicts unfavorable disease at final pathology in intermediate risk prostate cancer.
    Porcaro AB; Tafuri A; Panunzio A; Rizzetto R; Amigoni N; Cerrato C; Shakir A; Gallina S; Bianchi A; Cianflone F; Serafin E; Gozzo A; Di Filippo G; Migliorini F; Novella G; Brunelli M; Cerruto MA; Antonelli A
    Int Urol Nephrol; 2021 Dec; 53(12):2517-2526. PubMed ID: 34580803
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The Influence of Endogenous Testosterone Density on Unfavorable Disease and Tumor Load at Final Pathology in Intermediate-Risk Prostate Cancer: Results in 338 Patients Treated with Radical Prostatectomy and Extended Pelvic Lymph Node Dissection.
    Porcaro AB; Panunzio A; Tafuri A; Cerrato C; Gallina S; Bianchi A; Rizzetto R; Amigoni N; Gozzo A; Serafin E; Cianflone F; Migliorini F; Vidiri S; Di Filippo G; Novella G; Brunelli M; Shakir A; Pagliarulo V; Cerruto MA; Siracusano S; Antonelli A
    Urol Int; 2022; 106(9):928-939. PubMed ID: 35081537
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Positive independent association between preoperative endogenous testosterone density and tumor load density in surgical specimen of patients undergoing radical prostatectomy.
    Porcaro AB; Bianchi A; Gallina S; Serafin E; Mazzucato G; Panunzio A; Tafuri A; Montanaro F; Marafioti Patuzzo G; Baielli A; Artoni F; Vidiri S; Cianflone F; D'Aietti D; Brunelli M; Siracusano S; Cerruto MA; Antonelli A
    Urologia; 2024 Feb; 91(1):76-84. PubMed ID: 37526101
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Endogenous testosterone density is an independent predictor of pelvic lymph node invasion in high-risk prostate cancer: results in 201 consecutive patients treated with radical prostatectomy and extended pelvic lymph node dissection.
    Porcaro AB; Tafuri A; Panunzio A; Mazzucato G; Cerrato C; Gallina S; Bianchi A; Rizzetto R; Amigoni N; Serafin E; Cianflone F; Orlando R; Gentile I; Migliorini F; Zecchini Antoniolli S; Di Filippo G; Brunelli M; Pagliarulo V; Cerruto MA; Antonelli A
    Int Urol Nephrol; 2022 Mar; 54(3):541-550. PubMed ID: 35044553
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prostate-specific antigen vs prostate-specific antigen density as a predictor of upgrading in men diagnosed with Gleason 6 prostate cancer by contemporary multicore prostate biopsy.
    Oh JJ; Hong SK; Lee JK; Lee BK; Lee S; Kwon OS; Byun SS; Lee SE
    BJU Int; 2012 Dec; 110(11 Pt B):E494-9. PubMed ID: 22540236
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical implications of endogenous testosterone density on prostate cancer progression in patients with very favorable low and intermediate risk treated with radical prostatectomy.
    Porcaro AB; Tafuri A; Panunzio A; Cerrato C; Bianchi A; Gallina S; Vidiri S; D'Aietti D; Serafin E; Mazzucato G; Princiotta A; Brusa D; Brunelli M; Pagliarulo V; Cerruto MA; Antonelli A
    Asian J Androl; 2023 Jan; 25(5):556-63. PubMed ID: 36629157
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Total testosterone density predicts high tumor load and disease reclassification of prostate cancer: results in 144 low-risk patients who underwent radical prostatectomy.
    Porcaro AB; Tafuri A; Sebben M; Processali T; Pirozzi M; Shakir A; Amigoni N; Rizzetto R; Brunelli M; Migliorini F; Siracusano S; Artibani W
    Int Urol Nephrol; 2019 Dec; 51(12):2169-2180. PubMed ID: 31444696
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prostate-specific antigen levels and proportion of biopsy positive cores are independent predictors of upgrading patterns in low-risk prostate cancer.
    Porcaro AB; Inverardi D; Corsi P; Sebben M; Cacciamani G; Tafuri A; Processali T; Pirozzi M; Mattevi D; De Marchi D; Amigoni N; Rizzetto R; Cerruto MA; Brunelli M; Siracusano S; Artibani W
    Minerva Urol Nefrol; 2020 Feb; 72(1):66-71. PubMed ID: 30298710
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Association between Basal Total Testosterone Levels and Tumor Upgrading in Low and Intermediate Risk Prostate Cancer.
    Porcaro AB; De Luyk N; Corsi P; Sebben M; Tafuri A; Processali T; Cerasuolo M; Mattevi D; Cerruto MA; Brunelli M; Siracusano S; Artibani W
    Urol Int; 2017; 99(2):215-221. PubMed ID: 28245478
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Preoperative endogenous testosterone density predicts disease progression from localized impalpable prostate cancer presenting with PSA levels elevated up to 10 ng/mL.
    Porcaro AB; Bianchi A; Mazzucato G; Gallina S; Serafin E; Tafuri A; Cerrato C; Panunzio A; Vidiri S; D'Aietti D; Orlando R; Brusa D; Brunelli M; Siracusano S; Cerruto MA; Antonelli A
    Int Urol Nephrol; 2023 Jan; 55(1):85-92. PubMed ID: 36197572
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The ability of prostate-specific antigen (PSA) density to predict an upgrade in Gleason score between initial prostate biopsy and prostatectomy diminishes with increasing tumour grade due to reduced PSA secretion per unit tumour volume.
    Corcoran NM; Casey RG; Hong MK; Pedersen J; Connolly S; Peters J; Harewood L; Gleave ME; Costello AJ; Hovens CM; Goldenberg SL
    BJU Int; 2012 Jul; 110(1):36-42. PubMed ID: 22085203
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A biopsy-integrated algorithm for determining Gleason 6 upgrading risk stratifies risk of active surveillance failure in prostate cancer.
    Blute ML; Shiau JM; Truong M; Shi F; Abel EJ; Downs TM; Jarrard DF
    World J Urol; 2017 May; 35(5):729-735. PubMed ID: 27631325
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Outcomes of men with an elevated prostate-specific antigen (PSA) level as their sole preoperative intermediate- or high-risk feature.
    Faisal FA; Sundi D; Pierorazio PM; Ball MW; Humphreys EB; Han M; Epstein JI; Partin AW; Carter HB; Bivalacqua TJ; Schaeffer EM; Ross AE
    BJU Int; 2014 Dec; 114(6b):E120-E129. PubMed ID: 24731026
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Clinically predictive factors of Gleason score upgrading in patients after radical prostatectomy].
    Zuo Q; Zhang F; Huang Y; Ma LL; Lu M; Lu J
    Beijing Da Xue Xue Bao Yi Xue Ban; 2016 Aug; 48(4):603-606. PubMed ID: 29263497
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prostate-specific Antigen Density Is a Good Predictor of Upstaging and Upgrading, According to the New Grading System: The Keys We Are Seeking May Be Already in Our Pocket.
    Brassetti A; Lombardo R; Emiliozzi P; Cardi A; Antonio V; Antonio I; Aldo S; Tommaso R; Alberto P; Gianluca D
    Urology; 2018 Jan; 111():129-135. PubMed ID: 29032238
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Risk of Upgrading and Upstaging Among 10 000 Patients with Gleason 3+4 Favorable Intermediate-risk Prostate Cancer.
    Yang DD; Mahal BA; Muralidhar V; Nezolosky MD; Vastola ME; Labe SA; Boldbaatar N; King MT; Martin NE; Orio PF; Beard CJ; Hoffman KE; Trinh QD; Spratt DE; Feng FY; Nguyen PL
    Eur Urol Focus; 2019 Jan; 5(1):69-76. PubMed ID: 28753811
    [TBL] [Abstract][Full Text] [Related]  

  • 18. MRI-Based Prostate-Specific Antigen Density Predicts Gleason Score Upgrade in an Active Surveillance Cohort.
    Washington SL; Baskin AS; Ameli N; Nguyen HG; Westphalen AC; Shinohara K; Carroll PR
    AJR Am J Roentgenol; 2020 Mar; 214(3):574-578. PubMed ID: 31913068
    [No Abstract]   [Full Text] [Related]  

  • 19. Clinical and pathologic predictors of Gleason sum upgrading in patients after radical prostatectomy: results from a single institution series.
    Tilki D; Schlenker B; John M; Buchner A; Stanislaus P; Gratzke C; Karl A; Tan GY; Ergün S; Tewari AK; Stief CG; Seitz M; Reich O
    Urol Oncol; 2011; 29(5):508-14. PubMed ID: 19837614
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pathological upgrading in prostate cancer patients eligible for active surveillance: Does prostate-specific antigen density matter?
    Jin BS; Kang SH; Kim DY; Oh HG; Kim CI; Moon GH; Kwon TG; Park JS
    Korean J Urol; 2015 Sep; 56(9):624-9. PubMed ID: 26366274
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.